Logo image of ENDP

ENDO INTERNATIONAL PLC (ENDP) Stock Fundamental Analysis

NASDAQ:ENDP - Nasdaq - IE00BJ3V9050 - Common Stock - Currency: USD

0.2926  -0.02 (-5%)

After market: 0.26 -0.03 (-11.14%)

Fundamental Rating

1

Taking everything into account, ENDP scores 1 out of 10 in our fundamental rating. ENDP was compared to 194 industry peers in the Pharmaceuticals industry. ENDP may be in some trouble as it scores bad on both profitability and health. ENDP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ENDP was profitable.
ENDP Yearly Net Income VS EBIT VS OCF VS FCFENDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -1B -2B -3B

1.2 Ratios

Industry RankSector Rank
ROA -40.81%
ROE N/A
ROIC 8.07%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENDP Yearly ROA, ROE, ROICENDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 200 -200 -400

1.3 Margins

Industry RankSector Rank
OM 19.02%
PM (TTM) -93.31%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENDP Yearly Profit, Operating, Gross MarginsENDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ENDP is creating some value.
ENDP has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ENDP is higher compared to a year ago.
ENDP Yearly Shares OutstandingENDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M
ENDP Yearly Total Debt VS Total AssetsENDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 5B 10B 15B

2.2 Solvency

ENDP has an Altman-Z score of -3.02. This is a bad value and indicates that ENDP is not financially healthy and even has some risk of bankruptcy.
ENDP has a Debt/Equity ratio of -2.52. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -2.52
Debt/FCF N/A
Altman-Z -3.02
ROIC/WACC1.22
WACC6.62%
ENDP Yearly LT Debt VS Equity VS FCFENDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 1.86 indicates that ENDP should not have too much problems paying its short term obligations.
ENDP has a Quick Ratio of 1.62. This is a normal value and indicates that ENDP is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.62
ENDP Yearly Current Assets VS Current LiabilitesENDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 1B 2B 3B

More info and screens

0

3. Growth

3.1 Past

ENDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.08%.
The Earnings Per Share has been decreasing by -8.54% on average over the past years.
ENDP shows a decrease in Revenue. In the last year, the revenue decreased by -1.56%.
The Revenue has been decreasing by -5.68% on average over the past years.
EPS 1Y (TTM)-12.08%
EPS 3Y1.48%
EPS 5Y-8.54%
EPS Q2Q%-95.38%
Revenue 1Y (TTM)-1.56%
Revenue growth 3Y0.52%
Revenue growth 5Y-5.68%
Sales Q2Q%-20.27%

3.2 Future

ENDP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -34.53% yearly.
Based on estimates for the next years, ENDP will show a decrease in Revenue. The Revenue will decrease by -8.13% on average per year.
EPS Next Y-57.56%
EPS Next 2Y-45.48%
EPS Next 3Y-38.91%
EPS Next 5Y-34.53%
Revenue Next Year-18.43%
Revenue Next 2Y-12.85%
Revenue Next 3Y-9.64%
Revenue Next 5Y-8.13%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ENDP Yearly Revenue VS EstimatesENDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B
ENDP Yearly EPS VS EstimatesENDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.13, which indicates a rather cheap valuation of ENDP.
ENDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.54.
ENDP is valuated cheaply with a Price/Forward Earnings ratio of 0.33.
ENDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 0.13
Fwd PE 0.33
ENDP Price Earnings VS Forward Price EarningsENDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.29
ENDP Per share dataENDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

ENDP's earnings are expected to decrease with -38.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.48%
EPS Next 3Y-38.91%

More info and screens

0

5. Dividend

5.1 Amount

ENDP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENDO INTERNATIONAL PLC

NASDAQ:ENDP (8/25/2022, 10:28:44 PM)

After market: 0.26 -0.03 (-11.14%)

0.2926

-0.02 (-5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-09 2022-08-09/bmo
Earnings (Next)11-07 2022-11-07
Inst Owners0%
Inst Owner Change0%
Ins Owners2.12%
Ins Owner Change0%
Market Cap68.80M
Analysts42.86
Price Target1.02 (248.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.13
Fwd PE 0.33
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 7.29
EPS(TTM)2.33
EY796.31%
EPS(NY)0.9
Fwd EY306.77%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS11.83
BVpS-13.6
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.81%
ROE N/A
ROCE N/A
ROIC 8.07%
ROICexc N/A
ROICexgc 26.18%
OM 19.02%
PM (TTM) -93.31%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity -2.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.62
Altman-Z -3.02
F-Score5
WACC6.62%
ROIC/WACC1.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.08%
EPS 3Y1.48%
EPS 5Y-8.54%
EPS Q2Q%-95.38%
EPS Next Y-57.56%
EPS Next 2Y-45.48%
EPS Next 3Y-38.91%
EPS Next 5Y-34.53%
Revenue 1Y (TTM)-1.56%
Revenue growth 3Y0.52%
Revenue growth 5Y-5.68%
Sales Q2Q%-20.27%
Revenue Next Year-18.43%
Revenue Next 2Y-12.85%
Revenue Next 3Y-9.64%
Revenue Next 5Y-8.13%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A